2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review
JA Spertus, PG Jones, AT Sandhu, SV Arnold - Journal of the American …, 2020 - jacc.org
To improve the patient-centeredness of care, patient-reported outcomes have been
increasingly used to quantify patients' symptoms, function, and quality of life. In heart failure …
increasingly used to quantify patients' symptoms, function, and quality of life. In heart failure …
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update
L Blonde, GE Umpierrez, SS Reddy, JB McGill… - Endocrine Practice, 2022 - Elsevier
Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …
evidence-based recommendations for the comprehensive care of persons with diabetes …
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
JA Spertus, MC Birmingham, M Nassif, CV Damaraju… - Nature medicine, 2022 - nature.com
Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors
improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in …
improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in …
Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries
I Johansson, P Joseph, K Balasubramanian… - Circulation, 2021 - Am Heart Assoc
Background: Poor health-related quality of life (HRQL) is common in heart failure (HF), but
there are few data on HRQL in HF and the association between HRQL and mortality outside …
there are few data on HRQL in HF and the association between HRQL and mortality outside …
Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial
Background: Patients hospitalized for acute heart failure experience poor health status,
including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 …
including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 …
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left …
JJV McMurray, DL DeMets, SE Inzucchi… - European journal of …, 2019 - Wiley Online Library
Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to
reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes …
reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes …
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo …
Background Improving symptoms is a primary treatment goal in patients with obstructive
hypertrophic cardiomyopathy. Currently available pharmacological options for hypertrophic …
hypertrophic cardiomyopathy. Currently available pharmacological options for hypertrophic …
Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a …
Elevated levels of diastolic BP and especially systolic BP (SBP) are major risk factors for the
development of HF. 18, 19 One of the most impactful observations from the Framingham …
development of HF. 18, 19 One of the most impactful observations from the Framingham …
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart …
The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2011 and includes selected …
extensive evidence review was conducted through October 2011 and includes selected …